Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stock price target increased to $107.00, issued a research note today by Vetr Inc.
- Updated: September 22, 2016
Yesterday Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded 2.55% higher at $133.69. The company’s 50-day moving average is $131.16 and its 200-day moving average is $135.82. The last stock close price is down -1.57% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,175,594 shares of the stock were exchanged, down from an average trading volume of 1,757,970
Reporting as potential downside of -0.20%, Vetr Inc. raised the target price of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to $107.00
Previously on 9/22/2016, Wedbush reported about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) raised the target price from $0.00 to $132.00. At the time, this indicated a possible downside of -0.01%.
See Chart Below
Alexion Pharmaceuticals, Inc. has a 52 week low of $110.56 and a 52 week high of $193.45 with a P/E ratio of 335.90 The company’s market cap is currently $0.
In addition to Vetr Inc. reporting its target price, a total of 18 firms have reported on the stock. The consensus target price is $187.61 with 7 firms rating the stock a strong buy, 6 firms rating the stock a buy, 7 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.